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Abstract
There is increasing recognition that chronic diseases are a major challenge for health delivery
systems and treasuries. These are highly prevalent and costly diseases and frequency is expected
to increase greatly as the population of many countries ages. Chronic kidney disease (CKD) has not
received the same attention as other chronic diseases such as congestive heart failure; yet, the
prevalence and costs of CKD are substantial. Greater recognition and support for CKD may require
that the disease no longer be viewed as one continuous disease state. Early CKD stages require
less complex care and generate lower costs. In contrast, late-stage CKD is every bit as complex and
costly as other major chronic diseases. Health authorities may not recognize and fund CKD care ap-
propriately until late-stage CKD is deﬁned clearly as separate and distinct from earlier stages of
disease. In this review, we describe the burden of chronic diseases, consider the challenges and
barriers and propose processes to improve late-stage CKD care. In particular, we recommend the
need for improved continuity of care, enhanced use of information technology, multidisciplinary
care, timely referral to nephrologists, protocol use and improved patient engagement.
Keywords: care management; CKD; health systems; late-stage CKD
Global burden of chronic disease
The burden of chronic disease has a wide reach, affecting
individuals and health systems in low-, middle- and high-
income countries. The Global Non-Communicable Disease
(NCD) Action Plan, endorsed by the World Health Assembly
in 2008, identiﬁed cardiovascular disease, cancer, respira-
tory disease and diabetes as priority diseases since they
represent the bulk of NCDs and their development can
be attributed to risk behaviors which may be modiﬁable
through public health action (e.g. tobacco smoking, lack of
physical activity and unhealthy diet) [1]. As of 2012, half of
all adult Americans have one or more chronic health condi-
tions [2]. The prevalence of diabetes approaches 11% in
many countries, and 12.7 million new cases of cancer were
diagnosed in 2008 worldwide [3]. Globally, chronic NCDs
are the most common cause of death and morbidity. In
2008, 63% of all deaths worldwide (36 of 57 million) were
due to chronic disease, and this risk is projected to increase
by 15% between 2010 and 2020 [4]. Diabetes is a leading
cause of blindness, renal failure and limb amputation in
many countries [5, 6], and the number of stroke survivors
worldwide is estimated to reach 77 million by 2030 [7].
Without a coordinated prevention and management plan,
health systems across the globe are now faced with the
‘neglected epidemic of chronic disease’ [8].
The economic consequences of this burgeoning epi-
demic are massive, with impact on both individuals and
health systems. At the household and individual level,
chronic disease and poverty are inextricably linked. Low-
income men and women are at higher risk for chronic
disease, while the high cost of health care in many coun-
tries leads to loss of household income. Each year, 100
million people are pushed below the poverty line due to
out-of-pocket health-care costs [9]. At the national level,
in 2010 the USA spent $315 billion on cardiovascular
disease [10] and $157 billion on cancer care [11]. Chronic
diseases account for 84% of all health care spending in
the USA [12]. Estimated losses to national income from
cardiovascular disease and diabetes in 2005 were US $18
billion in China, and $9 billion in India [13]. As a result, in
2010 the World Economic Forum placed chronic diseases
among the most consequential and severe threats to eco-
nomic development [14].
Contrary to conventional thinking, the adverse conse-
quences of chronic disease are not an exclusive problem
of high-income nations. In sub-Saharan Africa, the preva-
lence of cardiovascular disease and type 2 diabetes has
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increased 10-fold from 1980 to 2008 [15]. Globally, 80% of
all deaths from chronic disease now occur in low- and
middle-income countries [16]. This rapid rise in resource-
poor nations places a burden on fragile health systems.
Although not identiﬁed directly as a priority disease
under the Global NCD Action Plan, chronic kidney disease
(CKD) has a complex and reciprocal relationship with other
chronic diseases. Worldwide, hypertension and diabetes
are the leading causes of CKD, and these diseases share
common, modiﬁable risk factors for development. CKD is
a major risk factor for development of cardiovascular dis-
ease [17], and also increases the risk of cardiovascular mor-
tality by 8- to 10-fold [18, 19]. Currently, the prevalence of
moderate to severe CKD (Stages 3–5) ranges from 5 to 7%
in most countries [20, 21], and as the prevalence of dia-
betes, hypertension and cardiovascular disease is projected
to rise, so will the global burden of CKD. In addition, low-
income status is also disproportionately associated with
CKD, with increased risk of albuminuria, progression of CKD
and end-stage renal disease (ESRD) [22–24].
Once ESRD develops, the clinical and economic burden
of disease is dramatically increased. Worldwide, ∼2
million people currently require renal replacement therapy
(RRT) for ESRD [25]. Developed countries spend 2–3% of
their entire national health-care budget on treatment for
ESRD [26]. Several developing countries do not have the
resources to provide any form of RRT. As a consequence, 1
million people die from untreated ESRD each year [27].
Overall mortality in ESRD patients on RRT is 10–100 times
higher than age-matched controls with normal renal
function [28]. Evidence-based management strategies
have been well demonstrated to slow the progression of
CKD [29, 30]. Unfortunately, awareness of disease in CKD
patients remains low (often <20%) [31], and remains an
important barrier to accessing care.
Late-stage CKD and barriers to optimal outcomes
The great burden imposed by chronic diseases on the
treasury and health-care systems of industrialized coun-
tries leads to an important, but perhaps overly focused
concentration on congestive heart failure (CHF) and rela-
ted diseases and less attention on the importance of CKD.
Yet, CKD affects a large number of patients and has a great
impact on health outcomes, quality-of-life experience and
total cost of health care. In 2011, CKD was present in 9.2%
of US Medicare beneﬁciaries and accounted for 18.2% of
costs [32]. From 2000 to 2011, while the total expenditures
of the Medicare system increased by ∼100%, the Medicare
costs for CKD increased by 380% [32]. The USA, in its
Healthy People 2020 campaign, is seeking to ‘reduce new
cases of chronic kidney disease (CKD) and its complications,
disability, death, and economic costs’ [32]. A similar focus
is in place in many other industrialized nations.
Public health success in CKD management may be
hampered by the prevailing view of CKD as one continuous
disease state, albeit with several stages. In fact, early-
stage CKD (Stages 1–3) is so qualitatively different than
late-stage CKD that a disservice is done by considering
CKD as a single disease state. Early-stage CKD is marked
by far less complexity than later stage disease, fewer
nephrologist ofﬁce visits and less of an impact on health
and economic outcomes. As an example, the cost of care
for both younger and older patients with CKD remains
somewhat constant for Stages 1–3 [32]. In late-stage CKD
(Stages 4–5), the focus of care shifts from preventing
disease progression to dialysis modality selection, prepar-
ation for ESRD and managing the complications of kidney
disease. The complexity of interacting diseases and deg-
radation of quality of life imposed by late-stage CKD
makes it a disease entity that is qualitatively and quanti-
tatively different than early-stage CKD. Outcomes in late-
stage CKD are generally suboptimal; reﬂected by the high
rates of hospitalization [33] and mortality [34], low rates
of home dialysis selection and pre-emptive transplant-
ation, and nearly 80% of patients initiate hemodialysis
with a catheter [32]. Indeed, late-stage CKD has much in
common with other chronic diseases such as CHF, ad-
vanced COPD and diabetes. Public health authorities may
ﬁnd it hard to view all of CKD with its inherent heterogen-
eity as important enough to prioritize in parallel with CHF
and advanced COPD. In contrast, late-stage CKD clearly is
worthy of prioritization and allocation of resources.
In the following section, we will review important barriers
imposed by the current model of health care, which affect
the care of patients with late-stage CKD. These barriers arise
out of an outdated model of medical management that is
well suited to treatment of acute medical problems and
health maintenance but poorly matched to the needs of pa-
tients with severe chronic conditions such as late-stage CKD.
Barriers to optimal care in late-stage CKD
Delayed referral to nephrologists
For many patients with CKD, referral to the nephrologist is
delayed until RRT initiation (Table 1 and Figure 1). Although
no deﬁnitive guideline exists to recommend when referral
should occur, at least a 12-month period prior to RRT pro-
vides most patients and nephrologists an adequatewindow
to optimize medical management, while educating and
preparing the patient for RRT. Despite this, in 2011, 73.7%
of incident dialysis patients either had never seen a neph-
rologist (42.1%) or had seen one for <12 months (31.6%).
These patients can have severe complications accompany-
ing late-stage CKD including anemia, mineral and bone
disease and volume overload, making their initiation of RRT
complex and prone to poor outcomes. While there are
many determinants of delayed referral, older patient age
and predominant care by an internist (versus primary care
practitioner) have been described [35]. Nephrologist care
prior to starting hemodialysis reduces catheter use at Day 1
of dialysis, but 65% of patients treated by a nephrologist in
the USA for more than 12 months still started dialysis with
a catheter in place [32]. Hence, even with timely referral to
the nephrologist, patient outcomes can still be improved,
demonstrating that multiple barriers can contribute to sub-
optimal care in late-stage CKD.
Episodic outpatient care
In late-stage CKD, most patients see their nephrologist
every 1–3 months. This may not be sufﬁcient as there are
Table 1. Barriers to optimal late-stage CKD care
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many adverse events that can occur between nephrologist
appointments. Volume status can ﬂuctuate, due to
dietary indiscretions or changes in medication, and can
result in hospitalization [36]. A busy outpatient ofﬁce does
not lend itself to the ongoing patient education required
to facilitate dialysis modality choice. Intermittent and
brief discussions of vascular access placement can result
in failure to secure a matured ﬁstula prior to RRT initiation;
a situation all too familiar to many nephrologists. The
current medical model of episodic nephrologist ofﬁce
visits is not well matched to the needs of the late-stage
CKD, these patients are complex and require bridging care
between ofﬁce visits to optimize medical conditions,
prevent complications, facilitate care plan progress and
strengthen patient education and self-management.
Fragmentation of care
Patients with late-stage CKD often have complex medical
issues and other concomitant chronic diseases that
require attention from several specialists, along with a
primary care physician. The web of multiple physicians
often results in fragmentation that arises from inadequate
communication and failure to develop an established,
uniﬁed care plan. Recommendations from the patient’s
nephrologist may conﬂict with other specialists, and vice
versa [37]. Physicians without expertise in nephrology
may add new medications that are potentially unsafe in
advanced kidney disease. In Italy, it was recently found
that up to 50% of CKD patients were prescribed an in-
appropriate drug [38]. A classic example of fragmentation
is the ‘dance’ between nephrologists and cardiologists.
Cardiology evaluation reveals dyspnea and the diuretic
dose is increased. Weeks later, the nephrologist sees the
patient and notes that the serum creatinine has in-
creased. The diuretic dose is withheld and perhaps the
angiotensin blocking agent is held as well. Without ad-
equate communication and coordination between both
specialists, the risk for hospitalization for decompensated
congestive heart failure or acute kidney injury may occur.
While multiple care providers are requisite for the complex
patient with late-stage CKD, the current health-caremodel
often results in medical care that is contradictory, rather
than complementary.
Fig. 1. The prevailing care model in late-stage CKD results in several barriers to achieving optimal outcomes. We propose pathways to improvement that
create a true collaborative care model.
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Inadequate patient education
Lack of disease state education results in patients ill
equipped to cope with the critical decisions imposed by
late-stage CKD and leaves patients prone to complications
of the disease. Educational needs extend broadly in late-
stage kidney disease [39]. Understanding of kidney disease
itself is important to motivate compliance and patient ac-
tivation. Diet education is an important non-pharmaco-
logical therapy that facilitates patient self-management;
however, patients can become frustrated with conﬂicting
diet instructions prescribed by different specialists. For pa-
tients to make an informed choice of dialysis modality,
education plays a key role. Insufﬁcient education results in
patients in many industrialized countries ‘choosing’ in-
center hemodialysis mostly by default [40]. Despite this, a
recent survey of US dialysis patients reported one-third of
dialysis patients received little or no education regarding
dialysis modality [41]. Globally, education of patients with
kidney disease may be improving. A recent European
Kidney Patients’ Federation (CEAPIR) survey found that
most patients felt a reasonable level of satisfaction with
education provided [42].
Poor communication
Several of the barriers discussed above are exacerbated by
poor communication between patient and physician, or
between physicians. For example physician to patient
communication often breaks down in the context of mo-
dality selection, thus impeding patient education. Patients
may resist the idea that a minimally symptomatic disease
(at present) will result in the need for a treatment as
drastic as dialysis in the near future. Cultural or religious
beliefs may give a false sense of security. The burden of
multiple comorbid conditions and the medicalization that
occurs when one’s life is dominated by physician appoint-
ments may make it difﬁcult to accept the addition of yet
another burden in dialysis treatment. Depression and
anxiety certainly play a central role as well [43].
Poor communication about modality selection can also
be related to nephrologist hesitancy. A physician’s desire
to avoid conﬂict and a reluctance to accept treatment
‘failure’ contributes to this hesitancy. Substantive modality
education cannot begin until these patient and nephrolo-
gist factors are addressed. Poor communication between
several physicians caring for a complex late-stage CKD
patient worsens fragmentation of care. Conﬂictingmedical
opinions can frustrate the patient, lead to unnecessary
delays in care, duplication of testing and even harm to the
patient if medications are being managed by several phy-
sicians independently.
Thus far, we have outlined the global burden of chronic
disease including CKD, described how the current model
of medical management may be poorly suited to patients
with chronic conditions and listed barriers to optimal out-
comes in patients with late-stage CKD. Changes to the
care delivery model could improve outcomes in these pa-
tients including increased pre-emptive transplantation,
home dialysis initiation, reduction in dialysis catheter use,
patient quality of life, hospitalization and mortality. We
propose an approach involving six tenets to speciﬁcally
address the failures of the current care model and subse-
quent barriers to optimal outcomes. These six tenets
include (i) continuity of care, (ii) enhanced use of informa-
tion technology, (iii) multidisciplinary care, (iv) timely re-
ferral to a nephrologist, (v) protocol use and (vi) patient
engagement. We will provide examples of how we have
implemented these approaches in a late-stage CKD
program at our institution, Healthy Transitions (HT) in
Late-Stage CKD. We will next brieﬂy describe the HT
program and then review our six proposed tenets of care.
Healthy transitions in late-stage CKD program
At our academic institution, we instituted a late-stage CKD
program in October, 2012. Healthy Transitions is a collab-
orative care management model. The two most important
components are a nurse care manager program and a re-
lational database informatics system. The HT program was
designed to meet the demands of late-stage CKD patients
through evidenced-based education, care coordination,
program protocols, innovative information/technology and
supportive services for patient self-management. To date,
the HT program has reduced hospitalizations, realized a
12.1% pre-emptive transplant rate, a 68.1% functioning
AV ﬁstula rate at Day 1 of dialysis and only a 22.7% total
catheter rate at initiation. Forty-one percent of patients
started dialysis without a hospitalization and 32.4% pa-
tients started on peritoneal dialysis. As we discuss over-
coming barriers to care, we will intersperse information
derived from the HTprogram experience.
Six tenets to overcome barriers and improve
outcomes in late-stage CKD
Continuity of care
In the previous section, we discussed how the current care
model is out of step with the needs of patients with
chronic diseases. One barrier, the episodic nature of neph-
rologist ofﬁce visits may leave the late-stage CKD patient
exposed between visits because there are so many
medical events, care processes that need to be achieved,
medication changes and other physician visits with
changes in treatment. In CHF, the problem of episodic
care (or how to manage the interappointment period) has
been addressed with both high-tech and lower tech solu-
tions. Implantable monitors help cardiologists monitor
volume status continuously. In the HT program, we have
utilized daily weight monitoring with computerized ana-
lysis of patterns to help prevent volume overload admis-
sions, which are common in late-stage CKD. Ultimately,
the most powerful bridge between nephrologist visits in
the HT program is a combination of low and high tech. It is
nurse care managers guided by a sophisticated informat-
ics system that help to monitor patients, provide educa-
tion and ensure that care plans are progressing between
appointments. In chronic disease, greater continuity of
care has demonstrable beneﬁt, a 50% reduction in hos-
pital readmissions in CHF [43], reduced symptomatology
in COPD [44] and our HT program’s reduction in hospitali-
zations and other improved outcomes in late-stage CKD.
Enhanced use of information technology
Electronic medical records. The current system where
high-risk patients oftenmove between different clinics and
subspecialties is prone to fail unless providers take an ac-
tive role in communicating with each other. An electronic
medical record (EMR) can greatly facilitate communication.
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This is best achieved when there is strong interoperability
between EMRs and robust and easy to use health informa-
tion exchanges. The result is a virtually connected
network of information that could greatly improve the efﬁ-
ciency and quality of care.
Well-designed EMRs have the ability to serve as plat-
forms for care coordination in chronic disease [45]. More-
over, providing patients with information access via an
electronic patient portal may improve patient engage-
ment [46].
Medical informatics. In the HT program, we use informat-
ics to link patient data to clinical protocols and to generate
alerts to the nurse care managers (Figure 2). Every mor-
ning, the nurse receives a report listing his/her full roster
of patients. Alerts are generated for a variety of problems
includingdelayedmodality selection, acuteweight changes,
medication discrepancies and incomplete advance direc-
tives. The alerts become very speciﬁc for critical pathway
steps related to optimal care processes. For example for
patients who have chosen hemodialysis as a modality,
alerts guide the nurse to facilitate sequential process steps
for AVF placement; making a surgical appointment, com-
pleting vessel mapping, scheduling surgery, facilitating
presurgical testing and then AV ﬁstula maturation moni-
toring. When EMRs are used in this way, they move from
passive data storage systems to valuable tools for care
management and coordination [47].
Multidisciplinary care
Medical management of patients with late-stage CKD re-
quires a care delivery model which supports the complex-
ity of care for this patient group. The individual
practitioner ofﬁce paradigm may not be an optimal care
delivery model in chronic disease [48]. There have been
many calls for multidisciplinary predialysis clinics as an ef-
fective means to provide standard care to the CKD popula-
tion [49]. Despite this, most countries still do not fund
multidisciplinary care.
A starting point for developing an effective late-stage
CKD multidisciplinary care model should be to examine
existing model processes in countries such as Canada and
England. In these systems, physicians utilize and imple-
ment a clinic model. CKD patients are referred and direc-
ted to see different disciplines at the same location
including physicians, mid-level providers, dedicated CKD
nurses, dieticians, pharmacists, social workers and vascu-
lar access nurses. The multidisciplinary care clinic has
certain advantages [50]. It is ideal for promoting the use
of protocols and reducing inappropriate care variability.
In the HT program, the most important aspect of mul-
tidisciplinary care is the role played by the nurse care
managers. The nurses act as a bridge between physicians,
improving the ﬂow of information. By managing care pro-
cesses between nephrologist visits, they mitigate the
problem of episodic care. They improve communication by
transmitting interappointment information about the
patient to the nephrologist. The role of the nurse care
manager is ‘supercharged’ by the informatics system that
provides daily alerts that support evidence-based and ef-
fective care (see above).
Timely referral to nephrologist
It is generally accepted that appropriate timing of referral
to a nephrologist to mitigate CKD complications is neces-
sary. The speciﬁc glomerular ﬁltration rate (GFR) level may
vary based on patient complexity and other factors,
but referral should never occur later than when the GFR is
< 30 mL/min. Patients that present to the nephrologist
‘late’ often experience complications such as anemia,
cardiovascular disease, mineral bone disease and mal-
nourishment [51], which make initiation of RRT complex
and prone to poor patient outcomes.
Insufﬁcient preparation for RRT is another consequence
of late referral to nephrologists. Data from a 2011 DOPPS
study suggests that lack of predialysis nephrology care is
associated with increased mortality. The USRDS reports
that 80% of incident HD patients 2011 began dialysis with
a catheter in place. Only 16.3% initiated HD with a mature
AV ﬁstula in place. In comparison, patients with more than
1 year under a nephrologist’s care were more likely to initi-
ate HD with a mature AV ﬁstula in place, at 31.9% [35].
Protocol use
In late-stage CKD, protocols and standardization of pro-
cedures could improve care and health outcomes. There
is often resistance to the use of protocols as not being
adequately responsive to individual patient needs (‘cook-
book’ medicine) [52], but suboptimal outcomes of late-
stage CKD patients indicate a need to reduce variability in
care. However, even strongly evidence-based protocols
and guidelines must have sufﬁcient ﬂexibility to enable
physician judgment. In the HT program, protocols were
Fig. 2. In a modern approach to optimal care of chronic disease, electronic patient information is used to improve care and communication.
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developed by a multidisciplinary team, often using exist-
ing practice guidelines. The HT protocols are activated by
insertion into programmed database queries and reports.
HT protocols for processes such as pre-emptive transplant
preparation, home safety evaluation and risk stratiﬁcation
are managed collaboratively by the nurse and nephrolo-
gist. We have found that, just as checklists help even the
most skilled pilots avoid errors, protocols help the HT care
team achieve consistent, highly reliable care.
Patient engagement
In patients with chronic disease, active patient invol-
vement in their health care can lead to better health
outcomes, and potentially lower costs [53]. Patient en-
gagement refers to a patient’s knowledge, ability and will-
ingness to manage his or her own health care, paired with
interventions which promote positive patient behavior
[53]. This process starts with patient and caregiver educa-
tion about chronic kidney disease and requires reinforce-
ment about natural history and complications. Education
must be provided at a level appropriate for the patient’s
learning ability. Patient engagement increases as he or
she expresses preferences in the treatment plan, and
ﬁnally treatment decisions are made based on patient
preferences, medical evidence and clinician judgment. An
important consideration is community engagement. A
good example comes from Gubbio, Italy, where important
improvements in blood pressure control were obtained in
a small town [54]. A late-stage CKD program in Taiwan
appears to be slowing progression to dialysis [55]. In the
HT program, education is provided by nephrologists and
nurses. It is preferred that key caregivers are present to
learn along with the patient. HT education covers many
subjects, but focuses on modality selection, diet and de-
pression recognition. For diet, the approach is ‘Low Salt
Every Day.’ In hypertension general compliance with a low
salt diet is acceptable. In contrast in late CKD, with
reduced salt and water excretion and frequent coexist-
ence of CHF and LVH, even a single day of sodium excess
may result in a hospitalization. Compliance must be very
consistent.
Conclusion
The incidence of chronic disease is increasing and poses a
major challenge to care providers and health systems
around the world. CKD, while not yet a major global focus,
affects a large number of patients and has great impact
on mortality, quality of life and health-care costs. In par-
ticular, care of the late-stage CKD patients is complex,
with many interacting medical comorbidities and multiple
care providers. Evolution from current care models to
more closely match the needs of late-stage CKD holds
promise. By promoting communication between the pat-
ient and care providers, engaging patients in their health
care, and leveraging innovative information technology,
we propose a transformation from our current, reactionary
health-care system into a proactive and collaborative care
model.
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